Clinical Trial Update: Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501） [Phase 2]

View source ↗

Summary

Phase 2 trial ARMOR2501 evaluating postoperative EGFR-TKI therapy for contralateral pulmonary nodules in patients with EGFR-mutant non-small cell lung cancer. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Sun Yat-sen University | Conditions: Lung Cancer (NSCLC) | Phase 2 | Status: RECRUITING